RECIST 1.1 in NSCLC Patients With EGFR Mutations Treated With EGFR Tyrosine Kinase Inhibitors: Comparison With RECIST 1.0

OBJECTIVE: Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 has been rapidly accepted in clinical trials as a standard measure to assess tumor response to therapy and is expected to improve response assessment, especially in genomically defined patients. The impact of RECIST 1.1 was compare...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Nishino, Mizuki, Cardarella, Stephanie, Jackman, David M., Ramaiya, Nikhil H., Rabin, Michael S., Hatabu, Hiroto, Jänne, Pasi A., Johnson, Bruce E.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2013
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3731976/
https://ncbi.nlm.nih.gov/pubmed/23789698
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2214/AJR.12.9668
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares